Literature DB >> 19757870

Utilities of the EQ-5D: transferable or not?

Saskia Knies1, Silvia M A A Evers, Math J J M Candel, Johan L Severens, André J H A Ament.   

Abstract

BACKGROUND: Within the framework of economic evaluations, the transferability of utility scores between jurisdictions remains unclear. The EQ-5D is a generic instrument for measuring health-related quality of life in economic evaluations, which can be used for comparing utility scores across countries. At present, the EQ-5D has several national value sets or tariffs. Nevertheless, utility estimates from foreign studies are often used directly for cost-effectiveness estimates, without adapting by applying the appropriate national value set. It is unclear if this practice is advisable, due to dissimilarities between the national value sets.
OBJECTIVES: To examine the effects of differences in national EQ-5D value sets on absolute and marginal utilities of health states, and determine to what degree these differences can be explained by methodological factors.
METHODS: First, the relative importance of the EQ-5D domains for the utility estimates was compared across the 15 value sets. Second, two hypothetical health states for a depressed patient and a pain patient (21232 and 33321) were selected for additional analysis, by comparing the utilities as scored by the value sets. The marginal influence of a one-level deterioration in a domain of these health states on the utility estimate was then determined. Third, the differences between the value sets were examined in more detail by using multilevel analysis to examine the role of methodological differences in the valuation studies.
RESULTS: Differences can be perceived between the national value sets of the EQ-5D in the preferences for the domains. The utilities of the two hypothetical health states show that the value sets differ substantially. Furthermore, the differences between the marginal values of the deteriorations are large, which can be explained partly by the type of valuation method. Other methodological differences also influence the value sets.
CONCLUSIONS: All results indicate that the differences between the EQ-5D value sets are considerable and should not be ignored. The differences can largely be explained by methodological differences in the valuation studies. The remaining differences may reflect cultural dissimilarities between countries. Therefore, further research should focus on investigating the transferability of utilities across countries or agreeing on a standard to perform valuation studies. For the time being, transferring utilities from one country to another without any adjustment is not advisable.

Entities:  

Mesh:

Year:  2009        PMID: 19757870     DOI: 10.2165/11314120-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  16 in total

Review 1.  A review of the use of health status measures in economic evaluation.

Authors:  J Brazier; M Deverill; C Green; R Harper; A Booth
Journal:  Health Technol Assess       Date:  1999       Impact factor: 4.014

2.  Estimating an EQ-5D population value set: the case of Japan.

Authors:  Aki Tsuchiya; Shunya Ikeda; Naoki Ikegami; Shuzo Nishimura; Ikuro Sakai; Takashi Fukuda; Chisato Hamashima; Akinori Hisashige; Makoto Tamura
Journal:  Health Econ       Date:  2002-06       Impact factor: 3.046

3.  A single European currency for EQ-5D health states. Results from a six-country study.

Authors:  Wolfgang Greiner; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan Busschbach; Martin Buxton; Paul Dolan; Paul Kind; Paul Krabbe; Arto Ohinmaa; David Parkin; Montserat Roset; Harri Sintonen; Aki Tsuchiya; Frank de Charro
Journal:  Eur J Health Econ       Date:  2003-09

4.  The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies.

Authors:  L M Lamers; J McDonnell; P F M Stalmeier; P F M Krabbe; J J V Busschbach
Journal:  Health Econ       Date:  2006-10       Impact factor: 3.046

5.  A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.

Authors:  Carlo A Marra; John C Woolcott; Jacek A Kopec; Kamran Shojania; Robert Offer; John E Brazier; John M Esdaile; Aslam H Anis
Journal:  Soc Sci Med       Date:  2005-04       Impact factor: 4.634

6.  Modeling valuations for EuroQol health states.

Authors:  P Dolan
Journal:  Med Care       Date:  1997-11       Impact factor: 2.983

7.  The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons.

Authors:  Adrian R Levy; Kris V Kowdley; Uchenna Iloeje; Eskinder Tafesse; Jayanti Mukherjee; Robert Gish; Natalie Bzowej; Andrew H Briggs
Journal:  Value Health       Date:  2007-12-17       Impact factor: 5.725

8.  The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Med Decis Making       Date:  2007-05-14       Impact factor: 2.583

9.  Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial.

Authors:  Claire A G Wolfs; Carmen D Dirksen; Alfons Kessels; Johan L Severens; Frans R J Verhey
Journal:  Arch Gen Psychiatry       Date:  2009-03

10.  How do Zimbabweans value health states?

Authors:  Jennifer Jelsma; Kristian Hansen; Willy De Weerdt; Paul De Cock; Paul Kind
Journal:  Popul Health Metr       Date:  2003-12-16
View more
  49 in total

1.  The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries.

Authors:  Raymond Oppong; Billingsley Kaambwa; Jacqueline Nuttall; Kerenza Hood; Richard D Smith; Joanna Coast
Journal:  Eur J Health Econ       Date:  2011-11-05

2.  Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets.

Authors:  Henry Bailey; Paul Kind
Journal:  Qual Life Res       Date:  2010-05-23       Impact factor: 4.147

3.  Utilities and QALYs in health economic evaluations: glossary and introduction.

Authors:  Gianni Virgili; Daniela Koleva; Livio Garattini; Rita Banzi; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-07-06       Impact factor: 3.397

4.  Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.

Authors:  K Lien; V C Tam; Y J Ko; N Mittmann; M C Cheung; K K W Chan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

5.  The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations.

Authors:  Sinaa A Al Aqeel; Mohammed Al-Sultan
Journal:  Saudi Pharm J       Date:  2011-12-24       Impact factor: 4.330

6.  Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

Authors:  Helen Dakin; Stavros Petrou; Mark Haggard; Sarah Benge; Ian Williamson
Journal:  Qual Life Res       Date:  2009-11-26       Impact factor: 4.147

7.  Quality of life, resource use, and costs related to hip fracture in Estonia.

Authors:  M Jürisson; H Pisarev; J Kanis; F Borgström; A Svedbom; R Kallikorm; M Lember; A Uusküla
Journal:  Osteoporos Int       Date:  2016-02-23       Impact factor: 4.507

8.  A value set for the EQ-5D based on experienced health states: development and testing for the German population.

Authors:  Reiner Leidl; Peter Reitmeir
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

9.  Impact of transformation of negative values and regression models on differences between the UK and US EQ-5D time trade-off value sets.

Authors:  Liv Ariane Augestad; Kim Rand-Hendriksen; Ivar Sønbø Kristiansen; Knut Stavem
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

10.  Comparison of pre- and post-operative health-related quality of life and length of stay after primary total hip replacement in matched English and German patient cohorts.

Authors:  Matthias Vogl; Reiner Leidl; Werner Plötz; Nils Gutacker
Journal:  Qual Life Res       Date:  2014-08-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.